(Q44788934)

6 December 2017

title

Esophageal cancer: Clinical Practice Guidelines for diagnosis, treatment and follow-up (English)

1 reference

ESMO Guidelines Working Group

6 December 2017

1 reference

5

object named as

ESMO Guidelines Working Group

1 reference

6 December 2017

M Stahl

1

1 reference

6 December 2017

W Budach

2

1 reference

6 December 2017

H-J Meyer

3

1 reference

6 December 2017

A Cervantes

4

1 reference

6 December 2017

language of work or name

1 reference

1 May 2010

1 reference

6 December 2017

1 reference

6 December 2017

volume

21 Suppl 5

1 reference

6 December 2017

page(s)

v46-9

1 reference

Cancer mortality in the European Union, 1970-2003, with a joinpoint analysis.

6 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ163

Positron-emission tomography and assessment of cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ163

Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ163

Curative endoscopic resection of early esophageal adenocarcinomas (Barrett's cancer).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ163

Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ163

Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ163

Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ163

Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ163

Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ163

Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ163

Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ163

Phase III trial of protracted compared with split-course chemoradiation for esophageal carcinoma: Federation Francophone de Cancerologie Digestive 9102.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ163

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ163

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ163

PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ163

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDQ163

1 reference

6 December 2017

1 reference